Gp100 (25-33), mouse sequence is found in residues 25 to 33 of the mouse self/tumor antigen glycoprotein (mgp100). Mgp100 is an enzyme involved in pigment synthesis, and the epitope fragment is expressed in both normal melanocytes and melanoma cells^[1].

1104.13

C₄₆H₆₉N₁₅O₁₇

212370-36-0

Glu-Gly-Ser-Arg-Asn-Gln-Asp-Trp-Leu

EGSRNQDWL

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

3.;;Recommended solution:

• [1]. Gal Cafri, et al. Production of LacZ inducible T cell hybridoma specific for human and mouse gp100₂₅₋₃₃ peptides. PLoS One. 2013;8(2):e55583.

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM^[1].

GP(33-41) sensitizes MC57 and T2-D^b cells to lysis with ED₅₀s of 0.9±0.6 and 2.5±0.7 nM^[1].
The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

226.98

CH₃TFKNVY

161928-86-5

Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Cys

KAVYNFATC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.

  [2]. Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37(3):798-806.

Binding experiments are performed at 37°C with T2-D^b cells, with a Millipore MultiScreen assay system. The H-2D^b LCMV antigen gp276-286 (SGVENPGGYCL) is radioiodinated, and the radiolabeled peptide is purified. Cells (2×10⁵ per well) are incubated in MultiScreen-HV 96-well filtration plates (pore size, 0.45 mm) with ¹²⁵I-gp276-286 (10 nM [final concentration]) for 90 min at 37°C. Cells are washed three times with ice-cold 1% BSA-PBS and by filtration under vacuum. The radioactivity bound to the cells retained on the filter is counted with a gamma counter. Direct binding is measured in the absence (total binding) or the presence (nonspecific binding) of a 1,000-fold excess (10 mM) of unlabeled gp276-286. Specific binding to H-2D^b is defined as the difference between total binding and nonspecific binding. Nontransfected T2 cells are used as a negative control under the same experimental conditions. Competition assays are performed with increasing concentrations (10^-10 to 10^-5 M) of unlabeled peptides competing against a fixed concentration (10^-8 M) of ¹²⁵Igp276-286. The percent inhibition of binding is calculated as 100 × [1-(counts per minute in the presence of competitor – counts per minute of nonspecific binding)/counts per minute of specific binding].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.

  [2]. Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37(3):798-806.